1228690-36-5,
AM095 (free acid),
AM-095 free acid,
AM-095,
AM095 free acid,
CHEMBL2182052,
AM-095 free base,
AM095,
[1,1'-Biphenyl]-4acetic acid,4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-,
AM-095 (free base),
LNDDRUPAICPXIN-GOSISDBHSA-N,
AM 095 (parent compound),
GTPL6988,
SCHEMBL2288084,
DTXSID10673108,
BCP09983,
EX-A1955,
AM 095,
BDBM50398127,
ZINC68247723,
CS-1129,
NCGC00378906-02,
HY-16040,
A14180,
W-5973,
(R)-2-(4'-(3-methyl-4-((1-phenylethoxy)carbonylamino)isoxazol-5-yl)biphenyl-4-yl)acetic acid,
[1,1'-Biphenyl]-4-acetic acid, 4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-,
{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid,
{4'-[3-Methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl][1,1'-biphenyl]-4-yl}acetic acid,
2-(4-{4-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]phenyl}phenyl)acetic acid,
2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid,
D06XGC,
AM-152,
AM-966,
AM-152),
BMS-986202,
LPA1 antagonists (fibrotic disease), Amira,
Lysophosphatidic acid antagonists (fibrotic disease), Amira,